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Abstract Previous studies have indicated that children
with inflammatory bowel disease (IBD) may not achieve
optimal bone mass. We evaluated the skeletal characteris-
tics in children and adolescents with IBD. This cross-sec-
tional cohort study comprised 80 IBD patients (median age
14.9 years, range 5–20) with a median disease duration of
3.4 years; 51 had ulcerative colitis, 26 Crohn disease, and 3
unspecified colitis. Eighty age- and gender-matched heal-
thy subjects served as controls. Areal bone mineral density
(aBMD), body composition, and vertebral fractures (VFs)
were assessed by DXA. Bone age (BA) was determined for
IBD patients. Findings were correlated with disease- and
treatment-related parameters and biochemistry. IBD
patients had lower BA-adjusted lumbar spine and whole-
body aBMD (p \ 0.001 for both) and whole-body BMC
adjusted for height (p = 0.02) than controls. Lean mass
and fat mass Z scores did not differ between the groups, but
IBD patients had lower whole-body BMC relative to
muscle mass (p = 0.006). Despite vitamin D supplemen-
tation in 48 %, vitamin D deficiency was common. In
IBD cumulative weight-adjusted prednisolone dose [150
mg/kg for the preceding 3 years increased the risk for
low whole-body aBMD (OR = 5.5, 95 % CI 1.3–23.3,
p = 0.02). VFs were found in 11 % of patients and in 3 %
of controls (p = 0.02). IBD in childhood was associated
with low aBMD and reduced bone mass accrual relative to
muscle mass; the risk for subclinical VFs may be increased.
These observations warrant careful follow-up and active
preventive measures.
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Current evidence of impaired bone health in children and
adolescents with inflammatory bowel disease (IBD)
encourages clinicians to screen and monitor bone health in
pediatric IBD patients [1]. Inflammation with increased
production of cytokines, growth failure, delayed puberty,
malabsorption, decreased physical activity, and the use of
glucocorticoids (GCs) are risk factors for suboptimal bone
health in pediatric patients with Crohn disease (CD) or
ulcerative colitis (UC).
Previous studies have shown that children with IBD may
not achieve their optimal peak bone mass. Low bone
mineral density (BMD) is increasingly reported in children
with CD and UC [2, 3]. Studies on children with IBD at the
time of diagnosis have demonstrated altered bone metab-
olism and geometry attributable to the underlying inflam-
matory, nutritional, and hormonal factors. Children with
CD have decreased trabecular volumetric BMD, decreased
cortical bone strength, and substantial muscle deficits at
diagnosis [4]. Transilial bone biopsies in newly diagnosed
IBD children have shown a mild cortical bone deficit and
low turnover of trabecular bone [5]. Despite improvements
in trabecular volumetric BMD and muscle mass, sub-
stantial musculoskeletal deficits persist after the onset of
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IBD treatment [4, 6]. A study on biomarkers of bone
metabolism has associated CD with suppressed bone for-
mation and increased bone resorption [7]. However, the
clinical consequences and long-term outcome of subopti-
mal bone health remain largely unknown.
Limited data are available on the fracture risk in pedi-
atric IBD patients with decreased bone mass [8]. An epi-
demiological study on 1,242 children with CD or UC and
3,287 healthy age- and gender-matched controls revealed
no increase in fracture risk. However, a subanalysis in
children younger than 12 years demonstrated a significant
positive association between IBD and fractures. Impor-
tantly, the study showed a trend toward increased preva-
lence of vertebral fractures (VFs), a significant indicator of
osteoporosis-related bone fragility in the pediatric age
group [9]. VFs have been reported in children with CD
[10], and they are not uncommon in young adults with CD
[11]. However, only few studies on children with IBD have
searched for subclinical VFs [5, 12].
In addition to impaired bone mass accrual, children with
IBD are at risk for growth failure and delayed pubertal mat-
uration. At diagnosis, CD is associated with lower height and
body mass index (BMI) for age [13, 14]. Follow-up studies
have found no catch-up in height [6, 14, 15]. Low BMD may
reflect retarded skeletal development due to growth failure
and delayed maturation. Previous reports have demonstrated
improved BMD Z scores when values are adjusted for bone
age (BA) instead of chronological age (CA) [16, 17].
The aim of our study was to evaluate the prevalence of
impaired bone health and fractures in children and adoles-
cents with IBD in comparison to healthy peers and to identify
clinical and treatment-related determinants of compromised
bone health. We analyzed anthropometric data, BMD, and
body composition in relation to both CA and BA.
Materials and Methods
Patients and Controls
This cross-sectional cohort study involved 80 (43 girls)
children and adolescents with IBD, diagnosed according to
the Lennard-Jones criteria [18]. All patients were treated
and enrolled into this study at the Outpatient Clinic for
Pediatric Gastroenterology at the Children’s Hospital,
Helsinki University Central Hospital. This hospital is a
tertiary center for pediatric gastroenterology patients, with
*150 patients with IBD at the time of the study between
June 2004 and December 2005. Inclusion criteria were age
between 4 and 20 years at the time of study enrollment and
IBD diagnosed at least 3 months prior to the date of
enrollment. In order to avoid any selection bias, consecu-
tive patients visiting the outpatient clinic were recruited for
the study. Subjects were ineligible if they had other med-
ical conditions unrelated to IBD that could potentially
affect growth or bone mineral accrual. The study protocol
was approved by the Ethics Committee, Children’s Hos-
pital, Helsinki University Central Hospital, and University
of Helsinki. Written informed consent was obtained from
all participants and/or their guardians.
Altogether 80 age- and gender-matched control subjects
were selected from a cohort of 186 healthy preliminary and
secondary school students in Helsinki. The characteristics
of the cohort have been previously published [19].
Patients and controls were assessed similarly: anthro-
pometry, BMD, and body composition measurements with
dual-energy X-ray absorptiometry (DXA) and a fasting
blood sample and urine sample were obtained from all
subjects.
Clinical Data Collection
Medical records of the patients were reviewed for disease
and treatment characteristics. Disease duration was calcu-
lated from the date of the first diagnostic gastroenterolog-
ical endoscopy. For each patient, weight-adjusted (dose per
body weight) cumulative doses of orally administered
prednisolone equivalents were calculated for 3 years pre-
ceding the study. Also, other drugs used either for treat-
ment prior to the study protocol or at the time of the study
were carefully registered. The patients and controls and/or
their parents filled out questionnaires on the study subject’s
fracture history; fracture localization and mechanism of
injury were recorded. Fractures were classified as low- or
high-energy traumas; fractures resulting from falls from
standing height or less were regarded as low-energy frac-
tures. Dietary intakes of Ca were obtained from a 3-day
dietary recall for 49 (61 %) IBD patients and using a food-
frequency questionnaire for 60 (75 %) controls. The aver-
age daily intake of Ca was calculated using the Finnish
National Food Composition Database (Fineli, version
2001), which is maintained by the Nutrition Unit, National
Institute of Health and Welfare (Helsinki, Finland). The
calculated total intake of Ca included intake from
supplements.
All patients were clinically assessed by a pediatric
gastroenterologist. Disease activity was scored using the
pediatric Crohn’s disease activity index (PCDAI) for
children with CD [20] and the pediatric ulcerative colitis
activity index (PUCAI) for children with UC [21]. A
patient was classified as having (1) ‘‘moderate–severe
disease’’ at examination if PCDAI was C30 or PUCAI was
C35; (2) ‘‘mild disease’’ if PCDAI was C10 and \30 or
PUCAI was C10 and \35; and (3) ‘‘inactive disease’’ if
PCDAI was \10 or PUCAI was \10 [20, 21]. Pubertal
status was determined clinically according to Tanner [22]
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in IBD patients. For healthy controls, pubertal stage was
determined as either pre-, mid-, or postpubertal based on
gonadotropin and sex steroid concentrations by a pediatric
endocrinologist (O. M.).
Growth Assessment
Height was measured with a Harpenden stadiometer
(Holtain, Crosswell, Crymych, UK) and weight in thin
underwear by an electric scale. Height SD score (height
Z score) was defined as a deviation of height, in SD units,
from the mean height for age and sex; weight was
expressed as a height-adjusted value, as a percentage of the
mean ratio in a normal population of the same gender and
height, according to the Finnish standards [23, 24]. BMI
was calculated as weight in kilograms divided by square of
height in meters, and BMI Z scores were determined by
British reference values [25].
Imaging Studies
BA was determined for patients from a plain radiograph of
the left hand according to Greulich and Pyle [26] by a
pediatric endocrinologist (O. M.), and it was considered
delayed or advanced when BA differed from the patient’s
CA by more than 1 year; the BA-adjusted BMD values
were used in these cases. BA films were not available for
controls.
Bone mineral content (BMC, g) and areal BMD (aBMD,
g/cm2) of the lumbar spine (L1–L4), total hip, and whole
body were measured with DXA (Hologic Discovery A,
pediatric software, version 12.4; Hologic, Waltham, MA).
aBMD values were transformed into Z scores and com-
pared with age- and gender-adjusted reference data for U.S.
Caucasian children. We calculated Z scores for BMC using
the least mean square algorithm with age- and gender-
adjusted reference data for nonblack children aged
7–17 years [27] and BMC Z scores for height Z score
according to both CA and BA [28]. The same DXA device
was used to assess body composition; both lean mass (LM)
and fat mass (FM) were registered. We calculated Z scores
for LM for height and percent FM for age using the least
mean square algorithm [29].
To detect VFs of the thoracic and lumbar spine, verte-
bral fracture assessment (VFA) images were obtained with
the same DXA equipment from all patients and controls.
Compression fractures were graded using a pediatric
method in which abnormal changes were classified as mild
(grade 2a, 20–49 % anterior height reduction) or severe
(grade 2b, C50 % anterior height reduction) wedge
deformities or mild (grade 3a, vertebral middle and/or
posterior height reduction 20–29 %) or severe (grade 3b,
vertebral middle and/or posterior height reduction C30 %)
compression deformities [30]. VFA images were assessed
independently by a pediatric radiologist (S. T.-S.) and a
pediatric endocrinologist (O. M.); discrepancies between
the readers were resolved by consensus.
Biochemistry
Blood hemoglobin, hematocrit, and erythrocyte sedimen-
tation rate were measured from IBD patients and plasma
Ca, phosphate, alkaline phosphatase, and albumin from
both patients and controls by standard methods. Serum
25-hydroxyvitamin D (S-25[OH]D) was assessed by high-
performance liquid chromatography (HPLC), and plasma
fasting parathyroid hormone was measured by a solid-
phase, enzyme-labeled chemiluminescent immunometric
assay (IMMULITE 2000, DPD; Diagnostic Products, Los
Angeles, CA); the reference range was 8–73 ng/L. Urine
was analyzed for Ca/creatine ratio (U-Ca/U-Crea).
Statistical Analyses
The t test was used when comparing clinical and bio-
chemical characteristics between the IBD and control
groups and between the CD and UC groups. For nonnor-
mally distributed parameters the Mann-Whitney nonpara-
metric U test was used. Differences in categorical variables
were tested using Pearson’s v2 test. Differences between
CA-adjusted and BA-adjusted parameters were tested with
a paired samples t test. The strength of the relationship
between lumbar spine aBMD Z score and the clinical
measurements was estimated by Kendall’s rank correlation
in the IBD and control groups. The relationship between
low aBMD Z score and cumulative weight-adjusted pred-
nisolone dose of [150 mg/kg as well as possible factors
associated with VFs in patients together were estimated
using logistic regression. p \ 0.05 was considered statis-
tically significant. All statistical analyses were performed




The study cohort included 80 IBD patients (43 girls) who
were between 5 and 20 years of age. Characteristics of the
patients are shown in Table 1. UC had been diagnosed in
49 (61 %), CD in 28 (35 %), and unspecified colitis in
three subjects at a median age of 10.4 years. At the time of
study assessment, the median age of the subjects was
14.9 years. BA was delayed in 27 (34 %) and advanced in
12 (15 %) subjects. Altogether 65 (81 %) patients had been
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on systemic GC treatment, and the cumulative weight-
adjusted prednisolone dose during the preceding 3 years
ranged from 13 to 393 mg/kg. At the time of the study,
most of the patients (65 %) had inactive disease and 10
(12.5 %) were not on any medication.
Bone Health in IBD Patients Compared to Healthy
Controls
Anthropometric data, bone health, and biochemical param-
eters of IBD patients and healthy controls are shown in
Table 2. Pubertal development was appropriate for CA in all
control subjects. Half of the age- and gender-matched control
subjects were postpubertal, while only 24 % of patients had
ended their pubertal development (p \ 0.001, Table 2). At
the time of study assessment, no difference in height
Z scores, weight-for-height percentages, or BMI Z scores
was observed between the groups when the values of patients
were corrected for BA. Based on Z scores relative to CA, IBD
patients had lower height Z scores than controls (Table 2).
aBMD Z scores adjusted for both CA and BA in IBD
patients are shown in comparison to healthy peers in Fig. 1.
BA-adjusted aBMD Z scores of lumbar spine, whole body,
and total hip were all significantly higher than CA-adjusted
scores. However, even the BA-adjusted lumbar spine
(IBD vs. control, median [range] –0.6 [–3.4 to ?1.9] vs. ?0.1
[–1.5 to ?2.6], p \ 0.001) and whole-body aBMD (–0.3
[–3.0 to ?2.3] vs. ?0.1 [–1.0 to ?2.4], p \ 0.001) Z scores
were significantly lower in the patients, whereas BA-
adjusted total-hip aBMD Z scores did not differ between
the patients and controls (–0.1 [–2.8 to ?2.4] vs. 0.0 [–1.9
to ?2.4], p = 0.06) (Fig. 1). Low BA-adjusted lumbar
spine aBMD (\ –1.0 Z score) was detected in 29 (36 %)
and low whole-body BMD in 18 (23 %) patients, whereas
low whole-body aBMD was observed in zero and low
lumbar spine aBMD in three (4 %) control subjects
(p \ 0.001 for both). Whole-body BMC Z scores adjusted
for both CA and BA are shown in Table 3. IBD patients
had significantly lower whole-body BMC Z scores than
control children even if the Z scores were adjusted for
height Z scores (Table 3). LM and FM Z scores did not
differ between the groups (Fig. 1). However, whole-body
BMC in relation to total LM was significantly lower in IBD
patients (IBD vs. control, 0.050 [0.039–0.068] vs. 0.051
[0.041–0.071] g/g, p = 0.006) indicating lower bone
mineral accrual in relation to muscle mass.
Table 1 Characteristics of the
80 patients with inflammatory
bowel disease





Characteristic n (%) or median (range)
Gender (boy/girl) 37 (46 %)/43 (54 %)
Diagnosis (ulcerative colitis/Crohn
disease/unspecified colitis)
49 (61 %)/28 (35 %)/3 (4 %)
Age at diagnosis (years) 10.4 (2.1–15.4)
Duration of disease (years) 3.4 (0.3–14.5)
Age at examination (years) 14.9 (5.1–20.1)
BA (years) 13.9 (3.3–19.0)
Delayed BA 27 (34 %)
Advanced BA 12 (15%)
Lifetime surgery (IBD-related) 8 (10 %)
Disease activity at study visit
(inactive/mild/moderate–severe)
52 (65 %)/22 (27 %)/6 (8 %)
Medication
5-ASA (lifetime/current) 80 (100 %)/58 (73 %)
Sulfasalazine (lifetime/current) 9 (11 %)/3 (4 %)
Azathioprine (lifetime/current) 18 (23 %)/14 (18 %)
Infliximab (lifetime/current) 9 (11 %)/4 (5 %)
Oral glucocorticoids (lifetime/current) 65 (81 %)/24 (30 %)
Cumulative weight-adjusted prednisolone
dose during preceding 3 years (mg/kg)
94 (13–393)
Duration of glucocorticoid treatment during
the preceding 3 years (days)
295 (24–912)
Biochemistry
ESR (mm/h) 11 (3–53)
Plasma albumin (g/L) 41 (30–50)
Hemoglobin (g/L) 131 (103–162)
HCT (%) 39 (32–48)
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In healthy control subjects, the lumbar spine aBMD
Z score correlated with the LM Z score (s = 0.29,
p \ 0.001), whereas no correlation with FM Z score or
S-25(OH)D level (p = 0.2 and p = 0.9, respectively) was
observed. In IBD patients, the BA-adjusted lumbar spine
aBMD Z score did not correlate with the LM Z score, the FM
Z score, S-25(OH)D level, or cumulative weight-adjusted
prednisolone dose in the preceding 3 years (Kendall’s s,
p = 0.4, p = 0.4, p = 0.8, p = 0.05). Cumulative weight-
adjusted prednisolone dose had a positive correlation with
FM Z score (s = 0.20, p = 0.04) and U-Ca/U-Crea ratio
(s = 0.23, p = 0.02). A cumulative weight-adjusted
Table 2 Anthropometry, biochemical parameters, and vitamin D status in 80 patients with IBD and 80 healthy controls
Median (range) or n (%) IBD patients (n = 80) Controls (n = 80) p
Age (years)* 14.9 (5.1–20.1) 14.4 (7.4–18.8) 0.5
Pubertal status (prepubertal/pubertal/postpubertal) 23 (29 %)/38 (47 %)/19 (24 %) 25 (31 %)/15 (19 %)/40 (50 %) \0.001
Height CA Z score –0.1 (–3.0 to 2.5) 0.5 (–2.3 to 3.2) 0.009
Height BA Z score 0.3 (–2.7 to 4.2) 0.2
Weight-for-height (%) 105 (87–156) 105 (84–192) 0.9
BMI CA Z score 0.1 (–1.9 to 2.5) 0.1 (–1.8 to 3.4) 0.1
BMI BA Z score 0.0 (–1.7 to 2.7) 0.4
P-Ca (mM) 2.35 (2.07–2.58) 2.33 (2.12–2.48) 0.05
P-Pi (mM) 1.32 (0.91–1.77) 1.37 (0.83–1.69) 0.2
P-ALP (U/L)* 165 (46–381) 202 (39–438) 0.3
P-PTH (ng/L) 40 (14–112) 38 (3–136) 0.4
U-Ca/U-Crea (mM/mM)* 0.22 (0.01–1.1) 0.15 (0.02–0.68) 0.002
S-25(OH)D (nM) 49 (16–102) 43 (17–82) 0.02
Vitamin D supplementation in use 38 (48) 17 (21) \0.001
S-25(OH)D \ 37.5 nM 24 (30) 28 (37) 0.4
The p values were taken from the independent samples t test or Pearson’s v2 test, except for variables marked with an asterisk, which were
analyzed with the Mann–Whitney U test
IBD inflammatory bowel disease, CA chronological age, BA bone age, P plasma, Ca calcium, Pi phosphate, ALP alkaline phosphatase, PTH
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Fig. 1 Lumbar spine (a),
whole-body (b), and total-hip
(c) aBMD Z scores and total fat
mass (e) Z scores adjusted for
calendar age (CA, dark gray
bars) and bone age (BA, light
gray bars) in the 80 pediatric
patients with IBD and in their
age- and gender-matched
control subjects (white bars).
Total lean mass for height
Z scores (d) in the IBD patients
(dark gray bars) and in control
subjects (white bars). The
bottom of each box indicates the
first, the cross line the second
(median), and the top the third
quartile of the variables.
Whiskers extend to the 5th and
95th percentiles. Outliers are
shown as open circles.
**p \ 0.01, ***p \ 0.001
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prednisolone dose[150 mg/kg during the preceding 3 years
increased the risk of low BA-adjusted aBMD in both the
lumbar spine (\ –1.0 Z score, odds ratio [OR] = 5.1, 95 %
confidence interval [CI] 1.2–21.6, p = 0.03) and the whole
body (OR = 5.5, 95 % CI 1.3–23.3, p = 0.02).
Although IBD patients received more often daily vitamin
D supplementation and their S-25(OH)D levels were higher
than in controls, 30 % of them were vitamin D–deficient (S-
25[OH]D \37.5 nM) (Table 2). All control subjects were
studied in the winter (October–March), whereas 39 (49 %)
of IBD subjects were assessed in the summer. When we
restricted the analysis to subjects examined in the winter, the
statistically significant difference between IBD subjects and
controls disappeared (IBD, n = 41 vs. control, n = 76;
S-25[OH]D 43 [17–97] vs. 42.5 [17–82] nM, p = 0.2) and
the prevalence of vitamin D deficiency (37 %) was equal in
both groups. Dietary intake of Ca was lower in IBD patients
(IBD, n = 49 vs. control, n = 60; 1,010 [256–2,820] vs.
1,490 [573–2,940] mg/day, p \ 0.001), whereas total intake
of Ca did not differ between the groups (1,400 [577–2,820]
vs. 1,500 [573–2,940], p = 0.1) and met the dietary rec-
ommendation in most of the subjects.
Differences Between UC and CD Patients
Disease history, anthropometric data, aBMD, and body
composition parameters of UC (n = 49) and CD (n = 28)
patients separately are shown in Table 4. Gender distri-
bution, age at diagnosis, duration of the disease, and dis-
ease activity at study assessment did not differ significantly
between these groups. Although the median cumulative
weight-adjusted prednisolone dose and duration of GC
treatment for the preceding 3 years were higher in UC
patients, the differences were not statistically significant.
There was a trend for higher prevalence of delayed BA in
CD patients. Height Z score, BMI Z score, and lumbar
spine and total-hip aBMD Z scores did not differ between
the UC and CD groups irrespective of CA or BA adjust-
ment (Table 4 and data not shown). The whole-body
aBMD Z score was lower in CD patients only relative to
CA (CD vs. UC, –0.8 [–3.0 to ?0.9] vs. –0.3 [–2.2 to
?1.7], p = 0.04) and not to BA (Table 4). However, the
FM Z score was lower in CD patients regardless of CA or
BA adjustment (Table 4 and data not shown). BA-adjusted
aBMD Z scores were significantly higher than CA-adjusted
Z scores both in the UC group (BA vs. CA, median, lumbar
spine, –0.6 vs. –0.8, p = 0.005; whole-body, –0.2 vs. –0.3,
p = 0.008) and in the CD group (lumbar spine, –0.4 vs.
–1.0, p = 0.03; whole-body, –0.4 vs. –0.8, p = 0.005).
Fracture History and VFs
No difference between the IBD and control groups was found
in the history of peripheral fractures. Altogether 12 periph-
eral fractures were reported in 9 (11 %) IBD patients and 28
fractures in 16 (20 %) control subjects (p = 0.2). One
fracture in both the IBD and control groups resulted from a
high-energy injury and the other fractures, from a low-
energy injury. Four vertebral compression fractures had been
diagnosed in one male patient 6 months after the diagnosis of
CD at the age of 13 years. VFA images of the spine were
available for 79 IBD patients and 79 control subjects.
Abnormal vertebral morphology was detected in 11 %
(n = 9) of IBD patients and 3 % (n = 2) of controls
(p = 0.02). Twenty vertebrae in IBD patients were frac-
tured; 16 (80 %) of them occurred in the thoracic and 4
(20 %) in the lumbar region. Six (30 %) of the fractures were
graded as mild anterior wedge deformity (2a) and 14 (70 %)
as mild compression deformity (3a). Eight (89 %) IBD
patients with VF were boys (p = 0.03). Abnormal vertebral
morphology was not associated with diagnosis of CD (3
[33 %] patients with VF vs. 24 [34 %] patients with normal
Table 3 Parameters of bone mineral content in 80 patients with IBD and 80 healthy controls
Median (range) IBD patients Controls p
Whole-body BMC (g) 1,832 (670–2,925) 1,943 (798–3,103) 0.07
Subtotal BMC (g) 1,462 (456–2,425) 1,585 (537–2,606) 0.1
Whole-body BMC CA Z score –0.16 (–3.41 to 2.17) 0.96 (–1.13 to 3.94) \0.001
Whole-body BMC BA Z score 0.38 (–2.64 to 2.70) 0.002a
Whole-body BMC CA Ht-Z scoreb 0.32 (–1.50 to 2.17) 0.55 (–0.93 to 3.02) 0.03
Whole-body BMC BA Ht-Z scorec 0.38 (–1.50 to 2.17) 0.02a
The p values were taken from the independent samples t test
IBD inflammatory bowel disease, BMC bone mineral content, CA calendar age, BA bone age, HtZ height Z score
a BA Z score in patients in comparison to CA Z score in controls
b n IBD patients vs. controls, 50 versus 66
c n IBD patients vs. controls, 58 versus 66
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vertebral morphology, p [ 0.99), mild to severe state of
disease (3 [33 %] vs. 24 [34 %], p [ 0.99), low lumbar spine
aBMD (3 [33 %] vs. 25 [36 %], p [ 0.99), cumulative
weight-adjusted prednisolone dose[150 mg/kg during the
preceding 3 years (1 [25 %] vs. 8 [17 %], p [ 0.99), vitamin
D deficiency (3 [33 %] vs. 21 [30 %], p [ 0.99), or use of
infliximab (1 [11 %] vs. 8 [11 %], p [ 0.99). When these
factors were modeled together in a logistic regression model
for VF, none of them became significant (p [ 0.8).
Discussion
Our cross-sectional cohort demonstrated lower lumbar
spine and whole-body aBMD Z scores in children and
adolescents with IBD in comparison to their healthy peers
even when pubertal delay was taken into account by BA
adjustment. Low BA-adjusted aBMD was observed in
23–36 % of patients, depending on the site of measure-
ment. Although the frequency of previous fractures did not
differ between IBD patients and controls, abnormal verte-
bral morphology was observed more often in children and
adolescents with IBD as a potential clinical consequence of
impaired bone health.
Although most of the patients had inactive disease, their
bone health was still impaired. The results on lower aBMD in
pediatric IBD patients are in concordance with previous
studies demonstrating persistently impaired BMD after
diagnosis of the disease [6, 14, 31, 32]. One-third of the
patients had delayed BA, and BA-adjusted aBMD Z scores
were significantly higher than CA-adjusted values, which
emphasizes the importance of correcting the BMD values for
delayed pubertal maturation when analyzing DXA results in
both CD and UC patients. Most previous studies that have
evaluated BA of pediatric IBD patients have reported sig-
nificant delay of BA, with a mean difference of 0.5–1.2 years
to CA [6, 16, 17, 32–34]. Two studies on IBD patients found
no difference between BA and CA [3, 5]. Sylvester et al. [31]
reported no significant difference between BMD Z scores
calculated for BA or height age in a cohort of 76 IBD
patients; the difference in the mean of CA and BA was 1 year
in 58 CD patients. Altogether, only a few studies have cor-
rected BMD Z scores of IBD adolescents for delayed BA.
Gokhale et al. [16] found that only girls with CD had sig-
nificantly lower BMD than their healthy sibling controls
when BMD Z scores were calculated for BA. Hill et al. [17]
reported significantly higher whole-body and lumbar spine
BA-adjusted aBMD Z scores than CA-adjusted scores for 32
CD patients, whereas the CA and BA aBMD Z scores were
not significantly different for 12 UC patients. In contrast to
these studies, our study with more UC patients demonstrated
higher BA aBMD Z scores in both CD and UC groups in
comparison to CA aBMD Z scores. However, the BA and
height Z-score adjustments did not completely normalize the
Table 4 Comparisons of 49 pediatric patients with ulcerative colitis to 28 pediatric patients with Crohn disease
Characteristics Median (range) or n (%) Ulcerative colitis (n = 49) Crohn disease (n = 28) p
Female gender 26 (53 %) 16 (57 %) 0.7
Age at diagnosis (years)* 10.5 (2.2–15.3) 11.2 (2.1–15.4) 0.6
Duration of disease (years)* 3.4 (0.3–14.5) 3.7 (0.5–14.1) 0.6
Disease activity at study visit (inactive/mild/moderate–severe) 33 (67 %)/13 (27 %)/3 (6 %) 16 (57 %)/9(32 %)/3 (11 %) 0.6
Cumulative weight-adjusted prednisolone dose during
the preceding 3 years (mg/kg)*
100 (13–313) 81 (19–393) 0.2
Duration of GC treatment during preceding 3 years (days)* 342 (50–851) 188 (24–912) 0.8
Age at examination (years)* 14.7 (5.1–19.2) 15.3 (8.7–20.1) 0.3
BA (years) 14.0 (3.3–19.0) 14.2 (7.8–19.0) 0.2
Delayed BA/appropriate BA/advanced BA 14 (29 %)/30 (60 %)/5 (19 %) 13 (46 %)/10 (36 %)/5 (18 %) 0.1
Pubertal status (prepubertal/pubertal/postpubertal) 15 (31 %)/24 (49 %)/10 (20 %) 5 (18 %)/14 (50 %)/9 (32 %) 0.2
Height BA Z score 0.1 (–2.7 to 4.2) 0.5 (–2.4 to 2.5) 0.9
BMI BA Z score 0.1 (–1.6 to 2.0) –0.1 (–1.7 to 2.7) 0.5
Lumbar spine aBMD BA Z score –0.6 (–2.5 to 1.6) –0.4 (–3.4 to 1.9) [0.9
Total-hip aBMD BA Z score –0.1 (–1.8 to 2.4) –0.5 (–2.8 to 1.3) 0.4
Whole-body aBMD BA Z score –0.2 (–2.2 to 2.3) –0.4 (–3.0 to 1.8) 0.2
Lean mass Z score –0.8 (–3.3 to 1.0) –0.7 (–2.3 to 1.0) 0.6
Fat mass BA Z score –0.5 (–2.4 to 1.7) –0.9 (–5.2 to 1.7) 0.02
The p values were taken from the independent samples t test or Pearson’s v2 test, except for variables marked with asterisk, which were analyzed
with the Mann–Whitney U test
GC glucocorticoid, BA bone age, BMI body mass index, aBMD areal bone mineral density
S. Laakso et al.: Impaired Bone Health in Pediatric IBD 127
123
Z scores, and the IBD patients’ BMD and BMC remained
significantly lower than those of controls. We did not detect
any significant difference in BA-adjusted aBMD Z scores
between CD and UC patients, whereas some previous studies
have suggested that low BMD is more evident in CD patients
than UC patients [16, 31]. Our findings thus show impaired
bone mass accrual in patients with IBD and confirm that the
low BMD values are not solely due to short stature or delayed
skeletal maturation.
Peripheral fractures were as frequent in IBD patients as
in controls. However, abnormal vertebral morphology was
observed more often in IBD patients. In patients, we were
able to associate abnormal vertebral morphology only with
male gender and not with any disease- or treatment-related
parameter. Thoracic VFs were more common than lumbar
VFs, as shown in previous studies on chronically ill pedi-
atric patients with increased risk for osteoporosis [35, 36].
Semeao et al. [10] reported on five female pediatric
patients (age range 10.6–16.8 years) with CD who had
developed VFs (15 thoracic, 7 lumbar). All had markedly
decreased BMD. One had VF only 4 months after onset of
CD, while in the others the time since diagnosis ranged
1–4 years. The largest epidemiological study on fracture
risk of pediatric IBD patients thus far has shown no
increased risk of diagnosed fractures but a strong trend
toward increased VFs in pediatric IBD patients, particu-
larly those with CD. Kappelman et al. [9] discussed their
power (1,242 patients with IBD, 737 CD) not to be ade-
quate to detect a significant association owing to the rarity
of VFs. Two studies with small numbers of patients found
no subclinical VFs by X-ray images [5, 12]. Although VFA
images are not as accurate for detecting VF as X-ray
images [37], they offer a practical and safe tool for
screening vertebral deformities. Our patients and controls
were assessed similarly, and therefore, the difference in
VFs is unlikely to be due to methodological issues but
rather reflects compromised bone strength in IBD.
Cumulative weight-adjusted prednisolone dose was
associated positively with U-Ca/U-Crea ratio, which was
higher in IBD patients than in healthy control subjects.
This finding is in line with the fact that GCs increase uri-
nary Ca excretion [38]. A cumulative weight-adjusted dose
of prednisolone of 150 mg/kg for the preceding 3 years
was associated with increased risk for low BA-adjusted
aBMD Z score for both the lumbar spine and whole body.
This shows the deleterious effect of high GC dose on bone
health. In previous studies on pediatric IBD patients,
cumulative GC dose has been associated with reduced
aBMD in one [16], while others have found no association
between GC treatment and bone parameters or bone min-
eral accrual rate [3, 6, 14, 31, 32, 34]. Longitudinal
assessment of bone structure in CD patients with peripheral
quantitative computed tomography has associated GCs
with increases in cortical volumetric BMD [4]. Several
studies have demonstrated a negative association between
cumulative GC dose and height Z score [2, 15, 34, 39].
Greater increases in FM Z scores have been associated with
cumulative CG exposure [15]. Cumulative weight-adjusted
prednisolone dose of the preceding 3 years was associated
positively with FM Z scores in our IBD patients. CD
patients had lower FM Z scores than UC patients. Our
small cross-sectional cohort of both UC and CD patients
did not demonstrate differences in LM Z scores in com-
parison to healthy peers, as opposed to previous reports on
body composition in IBD patients [4, 6, 15, 34, 39]. The
positive association between LM Z score and lumbar spine
aBMD Z score was found only in our control group and not
in the IBD group.
Although nearly half of the IBD patients were on vita-
min D supplementation, 30 % of them were vitamin
D–deficient. The prevalence of vitamin D deficiency did
not differ from that of their healthy peers living in the same
district of Helsinki (60N). Pappa et al. [40, 41] reported a
5.8–34.6 % prevalence of vitamin D deficiency in pediatric
IBD patients treated in a tertiary-care center in Boston
(42N). Since IBD subjects are at increased risk of com-
promised bone health, it is important to ensure adequate
vitamin D supplementation, regardless of the season and
latitude, to accomplish S-25(OH)D concentrations above
50 nmol/L. The optimal S-25(OH)D may be even greater
and the needed vitamin D dose may be significantly higher
than presently recommended in most countries; these
remain to be determined in future studies.
Our study has limitations that may explain some of our
findings. The power of the study was limited to exclude all
negative results, and we were not able to test differences in
smaller subgroups divided by, e.g., gender or pubertal
stage. Furthermore, due to limited data collection, we were
not able to estimate the effects of physical activity or
dietary factors on bone health. Ideally, we should have
included all IBD patients treated at our clinic but had to
limit the study to 80 patients. In order to avoid selection
bias, we recruited consecutive patients fulfilling the
inclusion criteria. It is possible that the limited size of our
cohort prevented us from identifying some factors that are
relevant to bone health in larger cohorts. Assessment of
pubertal maturation differed between patients and controls.
However, the BMD comparisons between patients and
controls were not based on pubertal staging, and therefore,
this limitation is unlikely to have an effect on our findings.
The cross-sectional study setting did not offer the possi-
bility to test causalities between impaired bone health and
the IBD itself or treatments. Longitudinal studies with
sufficient follow-up time beyond adolescence are needed to
clarify the risk and significance of reduced peak bone mass
in pediatric IBD patients. Screening of subclinical VFs
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with X-ray images is needed to estimate the real risk of
VFs in pediatric IBD patients [37].
In conclusion, our study shows that children and ado-
lescents with UC or CD have an increased risk for impaired
bone health in comparison to their healthy peers. IBD
patients had lower lumbar spine and total-body aBMD
Z scores, even after adjustment of the DXA results for BA.
A high weight-adjusted dose of prednisolone was associ-
ated with increased risk for low BA-adjusted aBMD. The
results of VFA images suggest a higher risk for subclinical
VFs in pediatric IBD patients. These observations warrant
careful follow-up and emphasize the need for more active
preventive measures, including adequate vitamin D sup-
plementation, in children and adolescents with IBD.
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30. Mäkitie O, Doria AS, Henriques F, Cole WG, Compeyrot S,
Silverman E, Laxer R, Daneman A, Sochett EB (2005) Radio-
graphic vertebral morphology: a diagnostic tool in pediatric
osteoporosis. J Pediatr 146:395–401
31. Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K,
Hawker G, Griffiths AM (2007) Natural history of bone metab-
olism and bone mineral density in children with inflammatory
bowel disease. Inflamm Bowel Dis 13:42–50
32. Pappa HM, Saslowsky TM, Filip-Dhima R, DiFabio D, Lahsinoui
HH, Akkad A, Grand RJ, Gordon CM (2011) Efficacy and harms
of nasal calcitonin in improving bone density in young patients
with inflammatory bowel disease: a randomized, placebo-con-
trolled, double-blind trial. Am J Gastroenterol 106:1527–1543
33. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM
(1993) Growth and clinical course of children with Crohn’s dis-
ease. Gut 34:939–943
34. Bechtold S, Alberer M, Arenz T, Putzker S, Filipiak-Pittroff B,
Schwarz HP, Koletzko S (2010) Reduced muscle mass and bone
size in pediatric patients with inflammatory bowel disease. In-
flamm Bowel Dis 16:216–225
35. Valta H, Jalanko H, Holmberg C, Helenius I, Mäkitie O (2008)
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